Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 4 |
List of Tables | 5 | 1 |
List of Figures | 5 | 1 |
CJ HealthCare Corp. Snapshot | 6 | 1 |
CJ HealthCare Corp. Overview | 6 | 1 |
Key Information | 6 | 1 |
Key Facts | 6 | 1 |
CJ HealthCare Corp. Research and Development Overview | 7 | 3 |
Key Therapeutic Areas | 7 | 3 |
CJ HealthCare Corp. Pipeline Review | 10 | 5 |
Pipeline Products by Stage of Development | 10 | 1 |
Pipeline Products Monotherapy | 11 | 1 |
Pipeline Products Combination Treatment Modalities | 12 | 1 |
Pipeline Products Partnered Products | 13 | 1 |
Partnered Products/Combination Treatment Modalities | 14 | 1 |
CJ HealthCare Corp. Pipeline Products Glance | 15 | 7 |
CJ HealthCare Corp. Late Stage Pipeline Products | 15 | 1 |
Pre-Registration Products/Combination Treatment Modalities | 15 | 1 |
Phase III Products/Combination Treatment Modalities | 16 | 1 |
CJ HealthCare Corp. Clinical Stage Pipeline Products | 17 | 1 |
Phase II Products/Combination Treatment Modalities | 17 | 1 |
Phase I Products/Combination Treatment Modalities | 18 | 1 |
CJ HealthCare Corp. Early Stage Pipeline Products | 19 | 1 |
IND/CTA Filed Products/Combination Treatment Modalities | 19 | 1 |
Preclinical Products/Combination Treatment Modalities | 20 | 1 |
Discovery Products/Combination Treatment Modalities | 21 | 1 |
CJ HealthCare Corp. Drug Profiles | 22 | 18 |
(ezetimibe + rosuvastatin calcium) | 22 | 1 |
Product Description | 22 | 1 |
Mechanism of Action | 22 | 1 |
R&D Progress | 22 | 1 |
(amlodipine besylate + candesartan cilexetil) | 23 | 1 |
Product Description | 23 | 1 |
Mechanism of Action | 23 | 1 |
R&D Progress | 23 | 1 |
(amlodipine besylate + rosuvastatin calcium + valsartan) | 24 | 1 |
Product Description | 24 | 1 |
Mechanism of Action | 24 | 1 |
R&D Progress | 24 | 1 |
(atorvastatin calcium + metformin hydrochloride) XR | 25 | 1 |
Product Description | 25 | 1 |
Mechanism of Action | 25 | 1 |
R&D Progress | 25 | 1 |
tegoprazan | 26 | 1 |
Product Description | 26 | 1 |
Mechanism of Action | 26 | 1 |
R&D Progress | 26 | 1 |
CJ-40006 | 27 | 1 |
Product Description | 27 | 1 |
Mechanism of Action | 27 | 1 |
R&D Progress | 27 | 1 |
darbepoetin alfa | 28 | 1 |
Product Description | 28 | 1 |
Mechanism of Action | 28 | 1 |
R&D Progress | 28 | 1 |
(amlodipine besylate + atorvastatin calcium + valsartan) | 29 | 1 |
Product Description | 29 | 1 |
Mechanism of Action | 29 | 1 |
R&D Progress | 29 | 1 |
somatropin biobetter | 30 | 1 |
Product Description | 30 | 1 |
Mechanism of Action | 30 | 1 |
R&D Progress | 30 | 1 |
NSI-566 | 31 | 1 |
Product Description | 31 | 1 |
Mechanism of Action | 31 | 1 |
R&D Progress | 31 | 2 |
CJ-14199 | 33 | 1 |
Product Description | 33 | 1 |
Mechanism of Action | 33 | 1 |
R&D Progress | 33 | 1 |
CJ-40010 | 34 | 1 |
Product Description | 34 | 1 |
Mechanism of Action | 34 | 1 |
R&D Progress | 34 | 1 |
CJ-40011 | 35 | 1 |
Product Description | 35 | 1 |
Mechanism of Action | 35 | 1 |
R&D Progress | 35 | 1 |
RQ-00000010 | 36 | 1 |
Product Description | 36 | 1 |
Mechanism of Action | 36 | 1 |
R&D Progress | 36 | 1 |
RQ-00000774 | 37 | 1 |
Product Description | 37 | 1 |
Mechanism of Action | 37 | 1 |
R&D Progress | 37 | 1 |
Small Molecules to Inhibit Janus Kinase for Rheumatoid Arthritis | 38 | 1 |
Product Description | 38 | 1 |
Mechanism of Action | 38 | 1 |
R&D Progress | 38 | 1 |
ranibizumab biosimilar | 39 | 1 |
Product Description | 39 | 1 |
Mechanism of Action | 39 | 1 |
R&D Progress | 39 | 1 |
CJ HealthCare Corp. Pipeline Analysis | 40 | 6 |
CJ HealthCare Corp. Pipeline Products by Target | 40 | 2 |
CJ HealthCare Corp. Pipeline Products by Route of Administration | 42 | 1 |
CJ HealthCare Corp. Pipeline Products by Molecule Type | 43 | 1 |
CJ HealthCare Corp. Pipeline Products by Mechanism of Action | 44 | 2 |
CJ HealthCare Corp. Recent Pipeline Updates | 46 | 9 |
CJ HealthCare Corp. Dormant Projects | 55 | 1 |
CJ HealthCare Corp. Locations And Subsidiaries | 56 | 1 |
Head Office | 56 | 1 |
Other Locations &Subsidiaries | 56 | 1 |
Appendix | 57 | 2 |
Methodology | 57 | 1 |
Coverage | 57 | 1 |
Secondary Research | 57 | 1 |
Primary Research | 57 | 1 |
Expert Panel Validation | 57 | 1 |
Contact Us | 57 | 1 |
Disclaimer | 58 | 1 |